Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and Stage IV non-small cell lung cancer

Investigational New Drugs

Volumn 16, Issue 1, 1998, Pages 81-85

  Haskell, Charles M ^a   Mendoza, Evelyn ^b   Pisters, Katherine M W ^c   Fossella, Frank V ^c   Figlin, Robert A ^d  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b MD Anderson Cancer Center ^*  (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adenosine 5' triphosphate; ATP; Non small cell lung cancer

Indexed keywords

ADENOSINE TRIPHOSPHATE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ANXIETY NEUROSIS; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DRUG INFUSION; DRUG TOXICITY; DYSPNEA; HEADACHE; HOT FLUSH; HUMAN; INFORMED CONSENT; INJECTION PAIN; INSOMNIA; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THORAX PAIN;

ADENOSINE TRIPHOSPHATE; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEST PAIN; DYSPNEA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING;

EID: 0031854157     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006018610986     Document Type: Article

References (16)

1. Trams EG, Kaufman H, Burnstock GA: Proposal for the role of ecto-enzymes and adenylates in traumatic shock. J Theor Biol 87:609-621, 1980
2. Rapaport E: Treatment of human tumor cells with ADP and ATP yields arrest of growth in the S phase of the cell cycle. J Cell Physiol 114:279-283, 1983
3. Beyer EC, Steinberg TH: Evidence that the gap junction protein connexin-43 is the ATP-induced pore of mouse macrophages. J Biochem 266:7971-7974, 1991
4. Lowenstein WR: The cell to cell channel of gap junctions. Cell 48:725-726, 1987
5. Vandewalle B, Hornez L, Revillion F, Lefebvre J: Effect of extracellular ATP on breast tumor cell growth, implication of intracellular calcium. Cancer Lett 8547-54, 1994
6. Zheng LM, Zychlinsky A, Liu C-C, Ojcius DM, Ding E, Young J: Extracellular ATP as a trigger for apoptosis or programmed cell death. J Cell Biol 112:279-288, 1991
7. Pranzi E, Djeu JY, Hoffman SL, Epling-Burnette PK, Blanchard DK: Lysis of leukemia cells by extracellular adenosine triphosphate: Mechanism and characterization of the adenosine triphosphate receptor. Blood 82:1578-1585, 1993
8. Rapaport E, Fontaine J: Anticancer activities of adenine nucleotides in mice are mediated through expansion of erythrocyte ATP pools. Proc Natl Acad Sci USA 86:1662-1666, 1989
9. Lasso de la Vega MC, Terradez P, Obrador E, Navarro J, Pellicer JA, Estrela JM: Inhibition of cancer growth and selective glutathione depletion in Ehrlich tumour cells in vivo by extracellular ATP. Biochem J 298:99-105, 1994
10. Abraham EH, Prat AG, Gerweck L, Seneveratne T, Arceci RJ, Kramer R, Guidotti G, Cantiello HF: The multidrug resistance (mdr 1) gene product functions as an ATP channel. Proc Natl Acad Sci USA 90:312-316, 1993
11. Maymon R, Maymon BBS, Cohenarmon M, Holtzinger ML, Leibovici J: Enhancing effect of ATP on intracellular Adriamycin penetration in human ovarian cancer cell lines. Biochem Biophys Acta 1201:173-178, 1994
12. Haskell CM, Wong M, Williams A, Lee L-Y: Phase I trial of extracellular adenosine 5′-triphosphate in patients with advanced cancer. Med Pediatr Oncol 27:165-173, 1996
13. Aaronson NK, Ahmedzia S, Bergman B: The European Organization for Research and Treatment of Cancer QLC-C30: A Quality of Life Instrument for use in International Clinical Trials in Oncology. J Natl Cancer Inst 85:365-376, 1993
14. Bergman B, Aaronson NK, Ahmedzia S: The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 30A:635-642, 1994
15. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
16. Figlin RA, Holmes EC, Turrisi AT: Non-small cell lung cancer. In: Haskell CM (ed) Cancer Treatment, 4th edition. W.B. Saunders Company, Philadelphia 1995, pp 385-413.